Page 2 - Usingc Reactive Protein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2.

Rachel frankSanjk patelGlobenewswire incEuropean commissionDrug administrationKiniksa pharmaceuticals ltdExchange commissionRegeneron pharmaceuticals incAbiprubart phaseChief executive officerDisease activity scoreUsingc reactive proteinSecondary efficacy endpointMean differenceLeast squaresRheumatoid factor